Journal
NEUROBIOLOGY OF AGING
Volume 78, Issue -, Pages 130-141Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2019.02.008
Keywords
Induced pluripotent stem cells; Embryonic stem cells; Drug screening; Drug discovery; High content screening; Neurodegeneration; Parkinson's disease; Alzheimer's disease; Motor neuron disease; Huntington's disease
Categories
Funding
- Innovative Medicines Initiative Joint Undertaking [115439]
- European Union's Seventh Framework Programme (FP7/2007-2013)
- UK Medical Research Council [MC_U12266B]
- UK Medical Research Council Dementia Platform UK [MR/M02492X/1]
- National Institute for Health Research Health Services and Delivery Research Programme [14/21/45]
- National Institute for Health Research Great Ormond Street Hospital Biomedical Research Center, Great Ormond Street Children's Charity [15GT29]
- Wellcome [106713/Z/14/Z]
- EFPIA companies
- MRC [MC_EX_G0800785] Funding Source: UKRI
- Wellcome Trust [106713/Z/14/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
Induced pluripotent stem cells and their derivatives have become an important tool for researching disease mechanisms. It is hoped that they could be used to discover new therapies by providing the most reliable and relevant human in vitro disease models for drug discovery. This review will summarize recent efforts to use stem cell-derived neurons for drug screening. We also explain the current hurdles to using these cells for high-throughput pharmaceutical screening and developments that may help overcome these hurdles. Finally, we critically discuss whether induced pluripotent stem cell-derived neurons will come to fruition as a model that is regularly used to screen for drugs to treat neurological diseases. (C) 2019 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
